Can MRI differentiate between atypical cartilaginous tumors and high-grade chondrosarcoma? A systematic review

Claudia Deckers, Maarten J Steyvers, Gerjon Hannink, H W Bart Schreuder, Jacky W J de Rooy & Ingrid C M Van Der Geest

To cite this article: Claudia Deckers, Maarten J Steyvers, Gerjon Hannink, H W Bart Schreuder, Jacky W J de Rooy & Ingrid C M Van Der Geest (2020) Can MRI differentiate between atypical cartilaginous tumors and high-grade chondrosarcoma? A systematic review, Acta Orthopaedica, 91:4, 471-478, DOI: 10.1080/17453674.2020.1763717

To link to this article: https://doi.org/10.1080/17453674.2020.1763717

© 2020 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation.
Can MRI differentiate between atypical cartilaginous tumors and high-grade chondrosarcoma? A systematic review

Claudia DECKERS 1, Maarten J STEYVERS 2, Gerjon HANNINK 3, H W Bart SCHREUDER 1, Jacky W J DE ROOY 2, and Ingrid C M VAN DER GEEST 1

1 Department of Orthopedics, Radboud University Medical Center, Nijmegen; 2 Department of Radiology, Radboud University Medical Center, Nijmegen; 3 Department of Operating Rooms, Radboud University Medical Center, Nijmegen, The Netherlands
Correspondence: claudia.deckers@radboudumc.nl
Submitted 2019-10-01. Accepted 2020-03-31.

The incidence of chondrosarcoma of bone appears to have been increasing during the last decade and is now reported to be the most common primary malignant bone tumor in several countries (Thorkildsen et al. 2018, van Praag et al. 2018). Conventional chondrosarcoma is the most common subtype of chondrosarcoma. Other subtypes of chondrosarcoma (e.g., juxtacortical, mesenchymal, or secondary chondrosarcoma) are rare and show different radiologic appearance and clinical behavior (Bindiganavile et al. 2015).

Conventional chondrosarcoma is classified into the histological grades 1 (current known as atypical cartilaginous tumor [ACT]), 2, and 3. The metastatic potential, and therefore the disease-specific survival, correlates with the histological grade (Fletcher et al. 2013, Laitinen et al. 2018, Thorkildsen et al. 2018). ACTs rarely metastasize and are therefore reclassified as an intermediate type of tumor, not a malignancy (Fletcher et al. 2013). Due to the increase in patients undergoing MRI examinations for joint-related complaints, the incidental detection of ACT has increased substantially (van Praag et al. 2018).

With the increasing incidence of ACT, clear radiologic criteria to differentiate ACT from high-grade chondrosarcoma (i.e., grades 2 and 3) become more and more important. Adequate staging of chondroid tumors at diagnosis is important as it determines both treatment and prognosis. High-grade chondrosarcomas behave aggressively. Between 10% and 30% of grade 2 and about 70% of grade 3 chondrosarcomas metastasize (Evans et al. 1977). Hence, high-grade chondrosarcoma (HGCS) requires wide en bloc resection with free surgical margins. In contrast, ACTs are intermediate tumors and can be treated either with intraslesional curettage and local adjuvant or nonoperatively with regular follow-up when located in the long bones (Deckers et al. 2016).

Background and purpose — Adequate staging of chondroid tumors at diagnosis is important as it determines both treatment and outcome. This systematic review provides an overview of MRI criteria used to differentiate between atypical cartilaginous tumors (ACT) and high-grade chondrosarcoma (HGCS).

Patients and methods — For this systematic review PubMed and Embase were searched, from inception of the databases to July 12, 2018. All original articles describing MRI characteristics of pathologically proven primary central chondrosarcoma and ACT were included. A quality appraisal of the included papers was performed. Data on MRI characteristics and histological grade were extracted by 2 reviewers. Meta-analysis was performed if possible. The study is registered with PROSPERO, CRD42018067959.

Results — Our search identified 2,132 unique records, of which 14 studies were included. 239 ACT and 140 HGCS were identified. The quality assessment showed great variability in consensus criteria used for both pathologic and radiologic diagnosis. Due to substantial heterogeneity we refrained from pooling the results in a meta-analysis and reported non-statistical syntheses. Loss of entrapped fatty marrow, cortical breakthrough, and extraosseous soft tissue expansion appeared to be present more often in HGCS compared with ACT.

Interpretation — This systematic review provides an overview of MRI characteristics used to differentiate between ACT and HGCS. Future studies are needed to develop and assess more reliable imaging methods and/or features to differentiate ACT from HGCS.
Due to the heterogenous composition of chondroid tumors, diagnostic biopsy is unreliable in assessing the genuine histological grade and malignant potential of chondrosarcomas (Laitinen et al. 2018). Therefore, physicians need to rely on imaging and clinical findings (e.g., pain is more common in HGCS) to differentiate ACT from HGCS. Imaging evaluation of cartilaginous and other bone tumors is generally based on multimodal assessment including at least conventional radiography and MRI (Nascimento et al. 2014).

During the most recent decades research has focused mainly on differentiating enchondroma from chondrosarcoma (Choi et al. 2013, Dous et al. 2014, Crim et al. 2015, Lisson et al. 2018). New insights have shown that both enchondroma and ACT located in the long bones can be observed without treatment (Deckers et al. 2016, Sampath Kumar et al. 2016, Chung et al. 2018). These insights make the differentiation between ACT and HGCS clinically relevant. Currently, literature on differentiating ACT from HGCS is sparse and clear radiologic criteria are lacking. Therefore, we performed a systematic review to provide an overview of MRI characteristics used to date to differentiate between ACT and HGCS.

Methods

The aim of this systematic review is to provide an overview of MRI characteristics used to differentiate between atypical cartilaginous tumors (ACT) and high-grade chondrosarcoma (HGCS). The inclusion criteria and method of analysis were specified in advance and documented in a PROSPERO protocol (CRD42018067959). This study was conducted and reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE guidelines.

Search strategy and selection of studies

The search strategy, composed of 3 elements (histology, MRI, and chondrosarcoma), was developed in collaboration with information specialists from the medical library of the Radboud University Medical Center Nijmegen, the Netherlands. The detailed search strategy can be found in Table 1 (see Supplementary data). No limits (e.g., language or publication date) were used.

The search strategy was carried out in Pubmed and Embase (last search performed July 12, 2018). Additionally, reference lists of the included studies and of relevant reviews were screened for potentially relevant papers.

After removal of duplicates, all unique records were imported into EROS (Early Review Organizing Software, Buenos Aires, Argentina) to allocate references randomly to 2 independent reviewers (CD, MS) responsible for screening and selection. Discrepancies were solved by discussion.

During the first screening phase, original studies (i.e., no case reports, conference proceedings, systematic reviews) were included if they mentioned the combination of chondrosarcoma, histology/pathology, and imaging in title and/or abstract. If not enough information was provided to make a valid judgment, the full text was evaluated. Full-text versions of all selected studies were screened and included if they met the pre-specified eligibility criteria: (1) preoperative MRI grading; (2) histopathological grading; (3) presence of MRI characteristics per chondrosarcoma grade; (4) primary central chondrosarcoma of bone; (5) adult patients.

Types other than primary central chondrosarcoma of bone (e.g., juxtacortical, mesenchymal, or secondary chondrosarcoma) were excluded as these different types of tumor show different radiologic appearance and clinical behavior (Bindiganavile et al. 2015).

Data extraction

2 independent reviewers (CD, MS) performed data extraction from each included study in a pre-piloted form. Information was extracted related to: study design, studied population, tumor location and size, tumor grade based on postoperative histology/pathology, pathology criteria used for diagnosis, type of MRI used, and MRI characteristics described per grade of chondrosarcoma (e.g., cortical breakthrough, soft tissue expansion).

If studies included other types of chondrosarcoma (e.g., juxtacortical, mesenchymal, or secondary chondrosarcoma), only data related to central ACT and high-grade chondrosarcoma were extracted.

If outcome data were presented incompletely, we tried to contact the authors to obtain the original data. A reminder was sent to those who did not reply within 2 weeks. When attempts to obtain original data failed, the article was excluded.

According to the WHO classification, ACTs (i.e., chondrosarcoma grade 1) were categorized as low-grade chondrosarcoma (LGCS). Grade 2, grade 3 and dedifferentiated chondrosarcomas were categorized as HGCS (Fletcher et al. 2013).

Quality appraisal

The quality of the included studies was assessed using STROBE for the assessment of observational studies (Table 2, see Supplementary data). We are aware of the fact that the authors of STROBE did not develop their tool for methodological quality assessment. However, due to the lack of validated and accepted tools for such assessments of observational studies, STROBE is often used for this purpose (da Costa et al. 2011). In accordance with other studies, only 10 of the 22 items of the STROBE checklist were used for methodological assessment (da Costa et al. 2011, Shemesh et al. 2017). The other 12 of the 22 items were found not to contribute to the methodological assessment.

In addition, we analyzed the quality of histopathology and MRI assessments. We checked whether there was (1) a description of the criteria used for diagnosis, (2) cited reference to consensus criteria used for diagnosis, and (3) if the diagnosis was established by an experienced musculoskeletal
pathologist/radiologist (Shemesh et al. 2017). In addition, we added whether the pathologist and/or radiologist was blinded. If the level of experience of the pathologist/radiologist was not specified in the article, the authors were contacted.

2 reviewers (CD, MS) independently scored each item as: well described (+), partly described (±), or poorly/not described (–). Discrepancies were solved by discussion.

No overall score was calculated, as we felt different study characteristics that are related to study quality cannot be judged as if they are of equal importance or interchangeable (Ioannidis 2011).

**Data analysis**

Heterogeneity was assessed by visual inspection of forest plots and quantified using the I^2^ and τ^2^. The latter were calculated even when the judgment was made that calculating a pooled estimate was not justifiable (Higgins et al. 2003). Before undertaking a meta-analysis, we first checked whether the studies were similar enough to justify combining their results. If the features of studies were deemed not sufficiently similar to combine in a meta-analysis, we displayed the results of included studies in a forest plot but suppressed the summary estimate (Faber et al. 2016, Mueller et al. 2018, Reeves et al. 2019). If possible, pooled estimates of proportions with their corresponding 95% confidence intervals were calculated using the logit transformation using inverse-variance weighting within a random effects model framework. Between-study variance was quantified using the τ^2^ statistic, estimated using the Sidik-Jonkman estimator. Data were analyzed using R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria) using the meta package.

Publication bias was assessed only if more than 10 studies were included in the meta-analysis.

Data for different MR modalities (conventional MRI, diffusion-weighted imaging, dynamic contrast enhancement, and quantitative texture analysis) were reported separately, as these outcome measures were found not to be comparable to pool.

MRI signal intensity, such as high signal on T1, can be related to several histopathological findings (e.g., hemorrhage, entrapped fat) and therefore does not necessarily indicate grade of chondrosarcoma. Therefore, we have chosen to exclude these MRI characteristics from our analysis.

**Funding and potential conflicts of interest**

There was no funding source for this study. None of the authors reported any conflict of interest.

**Results**

Conducting our search strategy in PubMed and Embase retrieved 2,132 unique records. 5 additional relevant articles were found via cross-referencing. 2,123 articles were excluded because they did not meet our eligibility criteria (Figure 1).

![Figure 1. PRISMA flow diagram.](image)

Errani et al. (2017) provided additional data on request. Consequently 14 articles were included in our systematic review (Table 3). 239 ACT and 140 HGCS were included in this systematic review. The following conventional MRI characteristics were reported by the included studies and analyzed: entrapped fat, perilesional bone marrow edema, internal lobular architecture, lobular outer margin, bone expansion, cortical thickening, scalloping, cortical breakthrough, periosteal edema, soft tissue edema, extra-osseous soft tissue expansion, ring and arc enhancement, solid enhancement, and central non-enhancing region. Due to substantial heterogeneity (I^2^ 50–90%) and insufficient information to further investigate this heterogeneity we decided to refrain from pooling the results and only provide non-statistical syntheses. The reported presence of conventional MRI characteristics in both ACT and HGCS is displayed in separate forest plots but we suppressed the summary estimates (Figure 2). Only the most commonly reported MRI characteristics are shown in Figure 2; all other MRI characteristics can be found in Figure 3 (see Supplementary data).

Both Kang et al. (2016) and Douis et al. (2018) compared maximum tumor size between ACT and HGCS. Kang et al. found a significant difference in tumor length between ACT (3.0 cm, SD 0.7 cm) and HGCS (7.4 cm, SD 2.7 cm), whereas Douis et al. did not find a difference in tumor length between ACT (11 cm, range 2.1–26 cm) and HGCS (13 cm, range 4.3–30 cm).

3 DWI studies were included describing apparent diffusion coefficient (ADC). Douis et al. (2015) found no statistically significant difference in both mean apparent diffusion coefficient (ADC) and minimum ADC between ACT and high-grade chondrosarcoma.

Welzel et al. (2018) found in their subgroup analyses that chondrosarcoma grade 1 had statistically significantly higher,
**Table 3. Study characteristics**

<table>
<thead>
<tr>
<th>Study</th>
<th>Study setting</th>
<th>Patients (n)</th>
<th>Tumor location (n)</th>
<th>MRI field strength</th>
<th>Intravenous contrast</th>
<th>MRI characteristics assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conventional MRI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crim et al. 2015</td>
<td>Retrospective</td>
<td>12 CS 1</td>
<td>Humerus (5), radius (1), femur (4), fibula (2)</td>
<td>NR</td>
<td>+</td>
<td>Length, deep endosteal scalloping, cortical breakthrough, soft tissue mass, gadolinium enhancement</td>
</tr>
<tr>
<td>Douïs et al. 2014</td>
<td>28 ACT</td>
<td>79 CS 1</td>
<td>Humerus (58), femur (98), tibia (24)</td>
<td>NR</td>
<td>–</td>
<td>Bone marrow edema, soft tissue edema, bone expansion, cortical thickening, cortical destruction, active periostitis, soft tissue mass, tumor length</td>
</tr>
<tr>
<td></td>
<td>36 CS 2</td>
<td>13 CS 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>23 Dediff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Douïs et al. 2018$$^\text{b}$$</td>
<td>Retrospective 1980–2016</td>
<td>15 CS 1</td>
<td>Humerus (10), femur (9), tibia (3), fibula (1)</td>
<td>3T</td>
<td>+</td>
<td>Tumor length, endosteal scalloping, bone marrow edema, soft tissue edema, cortical destruction, periosteal reaction, bone expansion, macroscopic fat, calcification, soft tissue mass, hemorrhage, 3 Dediff</td>
</tr>
<tr>
<td></td>
<td>3 CS 2</td>
<td>1 CS 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 Dediff$$^\text{a}$$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Errani et al. 2017</td>
<td>Retrospective 1986–2015</td>
<td>17 ACT</td>
<td>Humerus (5), femur (9), tibia (3)</td>
<td>1.5T</td>
<td>NR</td>
<td>Scalloping, soft tissue mass</td>
</tr>
<tr>
<td>Fayad et al. 2015</td>
<td>Retrospective 1991–2014</td>
<td>6 CS 2</td>
<td>Hands and feet (7)</td>
<td>1.5T</td>
<td>+</td>
<td>T1 signal$$^\text{c}$$, T1 heterogeneity$$^\text{c}$$, T2 hyperintense$$^\text{c}$$, T2 heterogeneity$$^\text{c}$$, bone marrow edema, soft tissue edema, gadolinium enhancement, soft tissue mass, bone marrow edema, bone expansion, cortical thickening, cortical destruction, active periostitis, soft tissue mass, tumor length</td>
</tr>
<tr>
<td></td>
<td>1 CS 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang et al. 2016</td>
<td>Retrospective 1993–2016</td>
<td>6 CS 1</td>
<td>Para-acetabular (21)</td>
<td>1.5T</td>
<td>+</td>
<td>Length, high signal foci on T1$$^\text{c}$$, high signal on T1–T2-STIR$$^\text{c}$$, soft-tissue mass, peritumoral edema, lobular border, acutabular cartilage destruction$$^\text{c}$$, diffuse signal changes in acetabulum$$^\text{c}$$, mass inside hip joint$$^\text{c}$$, femoral head involvement$$^\text{c}$$</td>
</tr>
<tr>
<td></td>
<td>15 HGCS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu et al. 2017</td>
<td>Retrospective 2008–2015</td>
<td>17 Dediff$$^\text{a}$$</td>
<td>NR</td>
<td>3T</td>
<td>+</td>
<td>Patterns of bone destruction, periosteal reaction, matrix mineralization, soft tissue mass, enhancement pattern, signal intensity</td>
</tr>
<tr>
<td>MacSweeney et al. 2003</td>
<td>Retrospective 1995–2005</td>
<td>8 Dediff$$^\text{a}$$</td>
<td>Humerus (2), femur (6)</td>
<td>1.0 or 1.5T</td>
<td>+</td>
<td>Soft tissue extension</td>
</tr>
<tr>
<td>Yoo et al. 2009</td>
<td>Retrospective 1999–2008</td>
<td>28 LG</td>
<td>Humerus (16), scapula (1), pelvic bone (9), femur (15), fibula (1)</td>
<td>1.0T or 1.5T</td>
<td>+</td>
<td>T1 signal$$^\text{c}$$, entrapped fat within the tumor, lobular architecture preservation, cortical destruction, soft tissue mass, gadolinium enhancement</td>
</tr>
<tr>
<td>Yoshimura et al. 2013</td>
<td>Retrospective 1996–2011</td>
<td>6 CS 1</td>
<td>Humerus (4), ulna (1), phalange (2), femur (7), tibia (1), calcaneus (1), rib (1)</td>
<td>NR</td>
<td>+</td>
<td>Entrapped fat within the tumor, lobular architecture, ring and arc enhancement, T1 signal$$^\text{c}$$, soft tissue mass, gadolinium enhancement</td>
</tr>
<tr>
<td></td>
<td>10 CS 2</td>
<td>1 CS 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffusion weighted imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Douïs et al. 2015$$^\text{b}$$</td>
<td>Retrospective 2012–2013</td>
<td>5 ACT</td>
<td>Humerus (19), rib (2), hand (3), spine (1), pelvis (5), femur (17), tibia (9)$$^\text{d}$$</td>
<td>3T</td>
<td>–</td>
<td>Apparent diffusion coefficient</td>
</tr>
<tr>
<td></td>
<td>15 CS 1</td>
<td>3 CS 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 CS 3</td>
<td>3 Dediff$$^\text{a}$$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Müller et al. 2016</td>
<td>Retrospective 2007–2012</td>
<td>8 CS 1</td>
<td>Skull base</td>
<td>NR</td>
<td>NR</td>
<td>Apparent diffusion coefficient</td>
</tr>
<tr>
<td>Welzel et al. 2018</td>
<td>Retrospective 2009–2014</td>
<td>24 CS 1</td>
<td>Skull base</td>
<td>3T</td>
<td>+</td>
<td>Apparent diffusion coefficient</td>
</tr>
<tr>
<td>Dynamic contrast-enhanced MRI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Douïs et al. 2018$$^\text{b}$$</td>
<td>Retrospective 1980–2016</td>
<td>15 CS 1</td>
<td>Humerus (10), femur (9), tibia (3), fibula (1)</td>
<td>3T</td>
<td>+</td>
<td>Dynamic contrast-enhanced (DCE) MRI parameters; angle of DCE-MRI curve, absolute enhancement and relative enhancement</td>
</tr>
<tr>
<td></td>
<td>3 CS 2</td>
<td>1 CS 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 Dediff$$^\text{a}$$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantitative texture analysis</td>
<td>Retrospective 2018</td>
<td>11 CS 1</td>
<td>NR</td>
<td>1.5 &amp; 3T</td>
<td>+</td>
<td>Quantitative texture analysis to assess tumor heterogeneity</td>
</tr>
</tbody>
</table>

NR = not reported.

$$^\text{a}$$ Dedifferentiated chondrosarcoma.

$$^\text{b}$$ Study mentioned twice as different imaging modalities are used in the same study.

$$^\text{c}$$ MRI characteristic not analyzed in our systematic review.

$$^\text{d}$$ 24 enchondroma tumors are included in description of tumor location.
Correct diagnosis of chondrosarcoma grade is crucial in determining both treatment and prognosis. Therefore, we performed a systematic review to provide an overview of MRI characteristics used to differentiate between ACT and high-grade chondrosarcoma.

Although we did not pool the overall results due to the considerable amount of heterogeneity, it appears that, compared with ACT, high-grade chondrosarcoma may present more often with the following MRI characteristics: loss of entrapped fatty marrow, cortical breakthrough, and extraossseous soft tissue expansion.

These MRI findings are in line with the histopathological findings described by several authors (Brien et al. 1997, Yoo et al. 2009, Logie et al. 2013).

In cartilaginous tumors production of chondroid matrix results in the typical lobulated growth pattern and the so-called ring and arc appearance (Logie et al. 2013). In HGCS these typical chondroid features become lost due to poor differentiation of cells. Chondrosarcoma cells actively infiltrate between mean, minimum, maximum, and normalized ADC values than grade 2 chondrosarcoma in the skull base.

Müller et al. (2016) measured the following ADC values in 8 chondrosarcoma grade 1 tumors of the skull base: mean ADC 2017 (SD 140) × 10⁻⁶ mm²/s. No ADC values of high-grade chondrosarcoma were measured.

Only 1 study was found that described dynamic contrast-enhanced (DCE) MRI parameters.

Douis et al. (2018) found no statistically significant difference for the various DCE-MRI parameters (angle of the DCE-MRI curve, absolute enhancement, and relative enhancement on DCE MRI) between LGCS and HGCS.

Lisson et al. (2018) performed an MRI-based 3D texture analysis in which they compared enchondroma with low-grade chondrosarcoma. No comparison with high-grade chondrosarcoma was made. The most promising texture parameters for differentiation were, among others, kurtosis (the magnitude of pixel distribution) in the contrast-enhanced T1-weighted images and entropy in non-contrast T1-weighted images.

The quality appraisal of diagnosis is presented in Table 4 (see Supplementary data). The individual scored items on the STROBE checklist of each study can be found in the Supplementary data. Our assessment of the reporting quality shows great variability in consensus criteria used for diagnosis for both pathologic and radiologic diagnosis. Only in 7 of 14 studies did an experienced pathologist in musculoskeletal oncology perform pathologic assessment. In the other 7 studies level of expertise was not mentioned. In 10 of 14 studies MRI assessment was performed by experienced musculoskeletal radiologists.

**Discussion**

Correct diagnosis of chondrosarcoma grade is crucial in determining both treatment and prognosis. Therefore, we performed a systematic review to provide an overview of MRI characteristics used to differentiate between ACT and high-grade chondrosarcoma.

Although we did not pool the overall results due to the considerable amount of heterogeneity, it appears that, compared with ACT, high-grade chondrosarcoma may present more often with the following MRI characteristics: loss of entrapped fatty marrow, cortical breakthrough, and extraossseous soft tissue expansion.

These MRI findings are in line with the histopathological findings described by several authors (Brien et al. 1997, Yoo et al. 2009, Logie et al. 2013).

In cartilaginous tumors production of chondroid matrix results in the typical lobulated growth pattern and the so-called ring and arc appearance (Logie et al. 2013). In HGCS these typical chondroid features become lost due to poor differentiation of cells. Chondrosarcoma cells actively infiltrate between...
individual fat cells, compressing and eventually replacing them (Brien et al. 1997). Absence of areas of entrapped fat is therefore highly indicative of HGCS. In addition, invasion of Haversian systems leads to periosteal reaction. Eventually there is destruction of the cortex and invasion of soft tissue (Brien et al. 1997). Yoo et al. (2009) found that on gross pathological evaluation, a central non-enhancing region corresponded to an area of hemorrhagic cyst, necrosis, and/or yellow-brown soft tissue mass reflecting a myxoid change, all characteristics of malignant tumors.

Due to the heterogeneity of cartilage tumors, areas of ACT can be seen in HGCS lesions. Therefore, the presence of MRI characteristics indicating ACT must be viewed in context and clinical findings must be taken into account. In addition, single MRI characteristics alone cannot differentiate between ACT and HGCS.

The assessment of the clinical relevance of our findings is not straightforward. Heterogeneity was substantial (I² 50–90%) in the majority of the analyses. Due to the considerable heterogeneity we decided not to perform a meta-analysis. Heterogeneity may be explained by either clinical and/or methodological diversity between included studies. Included studies showed great variability in tumor location within and between studies. Different bones (e.g., phalanges, femur) as well as types of bone (e.g., flat, long bones) were included in most studies, which might show different clinical behavior and radiologic appearance (Bindiganavile et al. 2015). We were unable to perform a sensitivity analysis on tumor location. In addition, heterogeneity might be caused by poor reliability between radiologists. The SLICED study group showed poor to slight reliability between radiologists for the subgroup of outcome-determined high-risk patients (SLICED Study Group 2007). However, the imaging modalities available for radiologists varied and different criteria were used. In those cases where MRI scans were available the reliability increased substantially. Zamora et al. (2017) showed fair interobserver agreement between orthopedic oncologists for diagnosis and grading of cartilaginous neoplasms. Nevertheless, no evaluator proposed observation or follow-up for lesions considered to be a malignant neoplasm.

**Limitations**

To reduce bias we excluded tumors other than primary central chondrosarcoma from our systematic review. Several studies were excluded as they included, e.g., secondary or periosteal chondrosarcoma as well and we were not able to extract data on the primary central chondrosarcoma (Varma et al. 1992, Geirnaert et al. 1993, De Beuckeleer et al. 1995, Geirnaert et al. 2000, Fritz et al. 2018). Excluding studies to reduce bias resulted in a limited number of tumors being included in this systematic review.

Several studies have shown that both radiological and histopathological diagnosis of chondrosarcoma is subject to low reproducibility, which may be caused by difficult and ambiguous definitions (SLICED Study Group 2007, Zamora et al. 2017). Different terminology has been used in chondrosarcoma literature during the past years, for example CLUMP (cartilaginous lesion of unknown malignant potential), borderline chondrosarcoma, or grade 0.5 CS, compromising comparability of studies. As can be seen in Table 4, several different grading methods have been used to assess the level of malignancy of chondrosarcoma. In addition, other imaging methods used (e.g., radiographs, CT) could have influenced the radiologist during MRI interpretation. Only Crim et al. (2015) and Fayad et al. (2015) stated that both radiographs and MRI were available for the radiologist. Other articles included did not report information on other imaging methods used but this could have been the case as combining different imaging methods is common practice.

Possible interreader variability of chondrosarcoma grading may have resulted in misclassification bias in our systematic review. We would recommend a standardized grading method and terminology for chondroid tumors to improve comparability between studies and decrease the amount of bias.

Third, we are aware of the fact that the authors of STROBE did not develop their tool for methodological quality assessment. Due to the lack of validated and accepted tools for such assessments for observational studies, STROBE is often used for this purpose (da Costa et al. 2011). We have used relevant items of the STROBE tool to give an overview of the methodology through the included papers. As shown by Mueller et al. (2018) there is considerable disagreement on how systematic reviews of observational studies should be done. We agree that there is a need for a comprehensive source of methodological guidance, in particular for quality assessment of observational studies.

This systematic review provides an overview of currently used MRI characteristics. Future studies are needed to develop and assess a reliable method for differentiating chondrosarcoma based on radiologic and clinical findings. Reliability could be increased by protocol-driven image acquisition for cartilaginous lesions and an easy to use grading system that could be reliably quantified.

From this systematic review it appears that MRI may possibly be helpful to differentiate ACT from HGCS. Extraosseous soft tissue expansion and cortical breakthrough appear to be present more often in HGCS and entrapped fat presents more often in ACT.

As a correct differentiation of ACT and HGCS is important, we recommend future studies to develop and assess more reliable imaging methods and/or features to differentiate ACT from HGCS.

**Supplementary data**

Tables 1, 2, and 4 and Figure 3 are available as supplementary data in the online version of this article, http://dx.doi.org/10.1080/17453674.2020.1763717


